Prostate Cell News Volume 11.48 | Dec 18 2020

    0
    39







    2020-12-18 | PCN 11.48


    Prostate Cell News by STEMCELL Technologies
    Vol. 11.48 – 18 December, 2020
    TOP STORY

    Targeting Therapy-Resistant Prostate Cancer via a Direct Inhibitor of the Human Heat Shock Transcription Factor 1

    Direct targeted heat shock factor 1 (HSF1) inhibitor robustly inhibited the HSF1 cancer gene signature and prostate cancer cell proliferation. It potently attenuated tumor progression in four therapy-resistant prostate cancer animal models, including an neuroendocrine prostate cancer model, where it caused profound tumor regression.
    [Science Translational Medicine]

    Abstract

    Virtual Conference Exhibition: Organoids
    PUBLICATIONSRanked by the impact factor of the journal

    Oncogenic Activation of PI3K-AKT-mTOR Signaling Suppresses Ferroptosis via SREBP-Mediated Lipogenesis

    Hyperactive mutation of PI3K-AKT-mTOR signaling protected cancer cells from oxidative stress and ferroptotic death through SREBP1/SCD1-mediated lipogenesis, and combination of mTORC1 inhibition with ferroptosis induction showed therapeutic promise in preclinical models.
    [Proceedings of the National Academy of Sciences of the United States of America]

    AbstractPress Release

    MUC1-C Activates the BAF (mSWI/SnNF) Complex in Prostate Cancer Stem Cells

    Scientists indicate that MUC1-C promotes neuroendocrine prostate cancer progression by integrating activation of E2F1 and esBAF with induction of NOTCH1, NANOG, and stemness.
    [Cancer Research]

    Abstract

    Phosphorylation-Dependent Regulation of SPOP by LIMK2 Promotes Castration-Resistant Prostate Cancer

    SPOP’s degradation stabilized AR, ARv7 and c-Myc, promoting oncogenicity. Phospho-resistant SPOP completely suppressed tumorigenesis in vivo, indicating that LIMK2-mediated SPOP degradation is a key event in prostate cancer progression.
    [British Journal of Cancer]

    Abstract

    SLFN11 Informs on Standard of Care and Novel Treatments in a Wide Range of Cancer Models

    To validate the specificity of an in-house developed IHC assay as well as to validate the correlation between schlafen 11 (SLFN11) and the response to different DNA-damaging agents and DNA damage-response inhibitors, SLFN11 knockout cells were generated in DU145 prostate cancer cells using CRISPR/Cas9.
    [British Journal of Cancer]

    Full Article

    GTSE1 Promotes Prostate Cancer Cell Proliferation via the SP1/FOXM1 Signaling Pathway

    Overexpression of G2 and S phase-expressed-1 (GTSE1) promoted proliferation in LNCaP cells, whereas silencing GTSE1 inhibited the growth of C4-2 cells.
    [Laboratory Investigation]

    Abstract

    Olfactomedin 4 Mediation of Prostate Stem/Progenitor-Like Cell Proliferation and Differentiation via MYC

    Using single-cell RNA sequencing analysis, researchers found that Olfactomedin 4 (OLFM4) was expressed in multiple stem/progenitor-like cell populations in both the normal prostate epithelium and RWPE1 cells and was frequently co-expressed with KRT13 and LY6D in RWPE1 cells.
    [Scientific Reports]

    Full Article

    Explore scientific events this January with the Science Events Calendar.
    REVIEWS

    Genomic and Phenotypic Heterogeneity in Prostate Cancer

    The authors summarize the manifestations of inter-tumoral and intra-tumoral heterogeneity in primary and metastatic prostate cancer. They emphasize the significant contribution of genomics studies in the field and discuss the importance of phenotypic changes.
    [Nature Reviews Urology]

    Abstract

    INDUSTRY AND POLICY NEWS

    TRHC’s DoseMeRx® Partners with Physiomics to Provide Precision Dosing for Oncology Medications

    Tabula Rasa HealthCare, Inc. (TRHC) announced it has entered into a partnership with Physiomics plc, the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalized medicine solutions. Initially, they will focus on the drug docetaxel, which is commonly used to treat prostate, breast and other cancers.
    [Tabula Rasa HealthCareâ„¢]

    Press Release

    Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC® Protein Degraders ARV-471 and ARV-110

    Arvinas, Inc. announced clinical program updates for its PROTAC® protein degraders ARV-471 and ARV-110. For ARV-110, the ongoing dose escalation portion of the Phase I/II trial in men with metastatic castration-resistant prostate cancer has provided additional evidence of anti-tumor activity and patient benefit, including a prostate specific antigen reduction of more than 50% rate of 40% in a molecularly defined patient population.
    [Arvinas, Inc.]

    Press Release

    FEATURED EVENT

    ISSCR: Vision 2030 A Forecast for the Field

    January 7 – 8, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Research Fellow – Prostate and Kidney Cancers

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    Research Associate / Assistant – Immuno-Oncology

    Scripps Research Institute – La Jolla, California, United States

    Senior Scientist – Tumor Evolution

    Pfizer – La Jolla, California, United States

    Associate Professor – Cancer Biology

    University of Cincinnati – Cincinnati, Ohio, United States

    Senior Investigator – Replication Stress and Chromatin Alterations

    NIH National Cancer Institute – Bethesda, Maryland, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Prostate Cell News Twitter